The Vaxzevria COVID-19 vaccine – benefit-risk ratio during clinical manufacturing

The first generation of COVID-19 vaccines were developed and approved in record time. As illustrated below, the pressure was immense, and practical solutions were often chosen during development in order to prevent delays in reaching market approval.

Please login or signup for this course to get access.

Register lost password

Glossary

Close course

Glossary

Support

Tools